Invion Ltd. · ASX:IVX
Invion — Shareholder Meeting (November 2018)
15 slides from Invion's shareholder meeting presentation, Nov 13, 2018
Slide 1: Invion Annual General Meeting: Chairman's Address
ASX ANNOUNCEMENT INVION ANNUAL GENERAL MEETING CHAIRMAN’S ADDRESS AND CEO PRESENTATION TO SHAREHOLDERS For personal use only Melbourne, Australia, 13 November 2018: Invion Limited (ASX:IVX) is pleased to provide the Chairman’s Address and CEO Presentation to Shareholders, to be presented to the Comp
Slide 2: Chairman's Address (continued)
ASX ANNOUNCEMENT With regards to research collaborations and the generation of data, we have partnered with some of Australia’s leading research institutes and engaged with a number of industry and scientific leaders to inform the development of IVX-P02 - an improved formulation of the Photosoft™ ag
Slide 3: Chairman's Address: Demerger and About Invion
ASX ANNOUNCEMENT The Cho Group has agreed to fund via a convertible loan $200,000 the initial overhead and operating costs of CAT to enable CAT to establish a pathway with the China Food and Drug Administration and appoint key service providers. We intend to move quickly: CAT is on track to file an
Slide 4: CEO's Report AGM 2018
For personal use only INVION CEO’s REPORT AGM 2018 13th November 2018
Slide 5: Developing a new photodynamic therapy with a novel photosensitiser
For personal use only Skin cancers INVION IS DEVELOPING A NEW PHOTODYNAMIC THERAPY WITH A NOVEL Lung cancer PHOTOSENSITISER (PHOTOSOFTTM TECHNOLOGY) TO IMPROVE THE TREATMENT Prostate cancer Ovarian cancer OF VARIOUS CANCERS
Slide 6: Photosoft technology advantages
PHOTOSOFT™ CURRENTLY AVAILABLE THERAPIES PHOTOSOFT™ TECHNOLOGY For personal use only ADVANTAGES 1 Activation at multiple wavelengths allows for both diagnostic and therapeutic use Water soluble Can be administered via various routes – 2 sublingual, topical and intravenous Positive immune response de
Slide 7: Photosoft and IVX-P02: new generation PDTs
For personal use only PhotosoftTM NEW • Chlorin-e4 based photosensitiser, multiple excitation peaks GENERATION • Blue light – strong red fluorescence for lesion visualization PDTs: • Red light – generation of ROS for directed tissue ablation PHOTOSOFTTM • Non-toxic and tolerated at high doses & IVX-
Slide 8: 2018: A year of rapid progress
2018 A YEAR OF RAPID PROGRESS For personal use only MANUFACTURING- AGENT HUDSON RESEARCH SKIN CANCER PROGRAM COLLOBARATION o AMT engaged to o Topical formulation for develop API o Dr Andrew Stephens IVX-PO2 FORMULATION skin cancer appointed to o New formulation tested o API manufacture well advisory
Slide 9: Highly experienced team
HIGHLY EXPERIENCED TEAM For personal use only CRAIG NEWTON LOUISE WHITE XENIA SANGO ALEXANDER DR SEBASTIAN DR ANDREW Chief Operating Manufacturing Regulatory BENNETT MARCUCCIO STEPHENS Officer and Quality and Clinical Technical Chemistry Advisory Advisor Development Advisor Advisor Board member
Slide 10: Hudson Institute collaboration: promising ovarian cancer results
HUDSON INSTITUTE COLLABORATION PROMISING OVARIAN CANCER RESULTS For personal use only
Slide 11: Invion in the news 2018
INVION IN THE NEWS 2018 For personal use only
Slide 12: Skin cancer program: a powerful new treatment option
SKIN CANCER PROGRAM A POWERFUL NEW TREATMENT OPTION For personal use only Invion will be pursuing superficial BCC Collaborations established: (sBCC) and Actinic Keratosis (AK) Formulytica Product Characteristics o Engaged to develop topical formulation of o Diagnostic and Therapeutic IVX-P02 o Topic
Slide 13: Key milestones ahead
KEY MILESTONES AHEAD For personal use only Multiple programs due to Skin cancers/pre-cancers (BCC and AK) enter trials in 2019 • Topical Indications: • Skin cancer BCC • Actinic Keratosis Lung cancer • Intravenous Indications: • Ovarian • Lung • Prostrate Prostate or Ovarian cancer
Slide 14: Market overview and price and volume
MARKET OVERVIEW PRICE AND VOLUME For personal use only 14 0 0.05 12 0 0.04 10 0 Share price ($) Volume (m) 80 $0.024 0.03 Clinical-stage life sciences 60 Focus company 40 0.01 (At 9 November 2018) 20 0 0.00 Mkt. Cap. A$131m 04 -Jan-1 7 21 -Jun-1 7 31 -Jan-1 8 18 -Jul-1 8 09 -Nov-1 6 16 -Aug-1 7 06 -
Slide 15: For personal use only
For personal use only